
UBS has downgraded Traton to Neutral citing that expectations appear full following a strong run, despite the company's robust fundamentals. As reported by Investing.com, Traton shares are up approximately 25% year-to-date following strong second-quarter order and margin performance. The analysts noted that while Traton's fundamentals remain robust, the current valuation has priced in most positive developments. UBS views Traton's fiscal 2026 margin guidance as conservative and believes the range could be raised by 50 basis points, but noted that consensus already appears positioned for this, limiting further upside from the update.
According to CNBC TV18, Gautam Chhaochharia of UBS expects Indian equities to remain range-bound in the near term while maintaining a more constructive 1-2 year outlook. The analyst noted that valuations remain a key concern, with several IT stocks already pricing in significant long-term growth. Despite high valuations, strong liquidity, and continued equity supply from promoters and private equity investors, Chhaochharia believes the downside appears relatively protected in most scenarios. The building blocks for economic growth recovery are now largely in place, with the stabilisation in crude oil prices reducing market uncertainty following West Asia tensions.
According to CNBC TV18, UBS remains positive on power, capital goods, and defence sectors over the longer term, but investors need to become more selective after strong gains. The firm's analysts are now focusing on individual stocks rather than taking an aggressive sector-wide approach. Power remains a long-term theme despite recent moderation, while the outlook for Indian IT services has become less negative with growing global clients challenging earlier bearish views. In the European truck market, UBS expects the second half of 2026 to improve on the first half as pricing comes through for European brands.
As reported by CNBC TV18, UBS is constructive on both discretionary consumption and selected staples companies. In staples, companies focused on volume growth, new product launches, and improving distribution could be entering a phase where these strategies show up more clearly in earnings. The healthcare sector has a long growth runway supported by low penetration and improving affordability. UBS remains positive on hospitals and diagnostics, with increasing penetration and the shift from informal to formal providers supporting long-term growth.